The latest issue of the HPRA Drug Safety Newsletter (DSN) includes important updates to support safe and appropriate use of the following medicines:
- Eligard (leuprorelin acetate depot injection)-Risk of lack of efficacy due to incorrect reconstitution and administration process.
- Beta interferons: Risk of thrombotic microangiopathy and nephrotic syndrome.
- Mycopheolate mofetil (CellCept) and Mycophenolic acid (Myfortic)-New warnings about the risks of hypogammaglobulinaemia and bronchiectasis.
- Tecfidera (dimethyl fumarate) - Progressive Multifocal Leukoencephalopathy (PML) has occurred in a patient with severe and prolonged lymphopenia.